EUVIMEDEUVIMED entdecken
Crossref

Cost-effectiveness analysis of four sampling and genomic testing strategies for patients with advanced non-small-cell lung cancer in Australia

Louisa G Collins, Peter T Simpson, Daniel Lindsay, Katia Nones, Kimberley Ryan, David Fairbairn, David Fielding

Pathology · 2026-06 · 58 (4) · 411-419

DOI: 10.1016/j.pathol.2025.12.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathology, 2026-06. Verfasst von Louisa G Collins und 6 weiteren Autor:innen. Beteiligte Einrichtung: Viertel Cancer Research Centre, Cancer Council Queensland, Brisbane, Qld, Australia; QIMR Berghofer Medical Research Institute, Brisbane, Qld, Austra…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Genetic Testing. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Medical Research Future Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Molecular testing informs therapy selection for patients with non-small-cell lung cancer (NSCLC) providing access to better treatments. However, the costs and benefits of alternative specimens and testing options are unknown. We modelled the cost-effectiveness of four molecular testing strategies involving combinations of biopsy (tissue aspirate versus liquid), sample (formalin-fixed paraffin-embedded cell block, cytology smears or cell-free DNA) and molecular test (single-gene, small panel or large panel). Outcomes included health system costs, life years and quality-adjusted life years (QALYs) from 5,000 Monte Carlo simulations. One-way and probabilistic sensitivity analyses and budget impact analyses were also undertaken. Over 5 years, the predicted mean costs per person (for combined tissue acquisition, testing and subsequent treatment) ranged from AU$87,915 for standard care to AU$98,712 for cytology smears and large panel sequencing. Outcomes were lowest for single-gene or small gene panel strategies (1.70-1.75 QALYs) and highest for the large-panel strategies (1.82-1.88 QALYs). Compared with standard care, the incremental cost per QALY gained ranged from $59,983 (95% uncertainty interval (UI): AU$48,598, $79,664) to AU$70,840 (95% UI: AU$57,697, AU$87,937). Findings were most sensitive to quality-of-life estimates and targeted therapy costs but not to biopsy, sampling or molecular testing costs. The budget impact of these new diagnostics is not inconsequential with costs up to 64% higher than those for current standard care. For people with advanced NSCLC, alternative sampling and comprehensive genomic testing combinations are potentially cost-effective in Australia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsGenetic TestingHumansCost-Effectiveness AnalysisCost-Benefit AnalysisAustraliaQuality-Adjusted Life YearsBiopsyGenomics

Stichwörter der Autor:innen

biopsycost-effectivenesscytology smearsgenomic sequencinglung cancer

Autor:innen und Institutionen

  • Viertel Cancer Research Centre, Cancer Council Queensland, Brisbane, Qld, Australia; QIMR Berghofer Medical Research Institute, Brisbane, Qld, Australia; Faculty of Health, Medicine and Behavioural Sciences, The Univers…
  • School of Biomedical Sciences, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane, Qld, Australia; UQ Centre for Clinical Research, Faculty of Health, Medicine and Behavioural S…
  • Viertel Cancer Research Centre, Cancer Council Queensland, Brisbane, Qld, Australia; QIMR Berghofer Medical Research Institute, Brisbane, Qld, Australia; UQ Centre for Health Services Research, Faculty of Health, Medici…
  • Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane, Qld, Australia.
  • Department of Thoracic Medicine, Royal Brisbane and Women's Hospital, Brisbane, Qld, Australia.
  • Pathology Queensland, The Royal Brisbane and Women's Hospital, Brisbane, Qld, Australia.

Förderung

  • Medical Research Future Fund

Zitieren

APA

Collins, L. G., Simpson, P. T., Lindsay, D., Nones, K., Ryan, K., Fairbairn, D., & Fielding, D. (2026). Cost-effectiveness analysis of four sampling and genomic testing strategies for patients with advanced non-small-cell lung cancer in Australia. Pathology, 58(4), 411-419. https://doi.org/10.1016/j.pathol.2025.12.007

Vancouver

Collins LG, Simpson PT, Lindsay D, Nones K, Ryan K, Fairbairn D, et al. Cost-effectiveness analysis of four sampling and genomic testing strategies for patients with advanced non-small-cell lung cancer in Australia. Pathology. 2026;58(4):411-419. doi:10.1016/j.pathol.2025.12.007

BibTeX
@article{Collins2026,
  author = {Collins, Louisa G and Simpson, Peter T and Lindsay, Daniel and Nones, Katia and Ryan, Kimberley and Fairbairn, David and Fielding, David},
  title = {Cost-effectiveness analysis of four sampling and genomic testing strategies for patients with advanced non-small-cell lung cancer in Australia},
  journal = {Pathology},
  year = {2026},
  volume = {58},
  number = {4},
  pages = {411--419},
  doi = {10.1016/j.pathol.2025.12.007}
}
Kostenlos starten →